Busulfan, Fludarabine, and Alemtuzumab Conditioning and Unrelated Cord Blood Transplantation in Children with Sickle Cell Disease

Biology of Blood and Marrow Transplantation

Volumn 19, Issue 4, 2013, Pages 676-677

  Radhakrishnan, Kavita ^a   Bhatia, Monica ^a   Geyer, Mark B ^b   del Toro, Gustavo ^c   Jin, Zhezhen ^a   Baker, Courtney ^a   Harrison, Lauren ^e   Morris, Erin ^e   Baxter Lowe, Lee Ann ^d   Cairo, Mitchell S ^e  

^a Och Spine at New York Presbyterian Hospitals   (United States)

^b MASSACHUSETTS GENERAL HOSPITAL   (United States)

^c WYCKOFF HEIGHTS MEDICAL CENTER   (United States)

^d UNIVERSITY OF CALIFORNIA   (United States)

^e NEW YORK MEDICAL COLLEGE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ALEMTUZUMAB; BUSULFAN; FLUDARABINE; MYCOPHENOLIC ACID 2 MORPHOLINOETHYL ESTER; TACROLIMUS;

ACUTE GRAFT VERSUS HOST DISEASE; ADENOVIRUS INFECTION; CANDIDIASIS; CHILD; CLINICAL ARTICLE; CORD BLOOD STEM CELL TRANSPLANTATION; CYTOMEGALOVIRUS INFECTION; ENGRAFTMENT; EVENT FREE SURVIVAL; FEMALE; GRAFT FAILURE; HUMAN; IMMUNOSUPPRESSIVE TREATMENT; INFANT; LETTER; MALE; NEUTROPHIL COUNT; OVERALL SURVIVAL; PRESCHOOL CHILD; SCHOOL CHILD; SICKLE CELL ANEMIA; UNRELATED DONORS; VIRUS PNEUMONIA;

ANEMIA, SICKLE CELL; ANTIBODIES, MONOCLONAL, HUMANIZED; BUSULFAN; CHILD; CHILD, PRESCHOOL; CORD BLOOD STEM CELL TRANSPLANTATION; FEMALE; GRAFT REJECTION; GRAFT SURVIVAL; HUMANS; INFANT; MALE; MYELOABLATIVE AGONISTS; TRANSPLANTATION CONDITIONING; UNRELATED DONORS; VIDARABINE;

EID: 84875536038     PISSN: 10838791     EISSN: 15236536     Source Type: Journal    
DOI: 10.1016/j.bbmt.2013.02.002     Document Type: Letter

References (10)

1. Kamani N.R., Walters M.C., Carter S., et al. Unrelated donor cord blood transplantation for children with severe sickle cell disease: results of one cohort from the phase II study from the Blood and Marrow Transplant Clinical Trials Network (BMT CTN). Biol Blood Marrow Transplant 2012, 18:1265-1272.
2. Bradley M.B., Satwani P., Baldinger L., et al. Reduced intensity allogeneic umbilical cord blood transplantation in children and adolescent recipients with malignant and non-malignant diseases. Bone Marrow Transplant 2007, 40:621-631.
3. Geyer M.B., Jacobson J.S., Freedman J., et al. A comparison of immune reconstitution and graft-versus-host disease following myeloablative conditioning versus reduced toxicity conditioning and umbilical cord blood transplantation in paediatric recipients. Br J Haematol 2011, 155:218-234.
4. Styczynski J., Tallamy B., Waxman I., et al. A pilot study of reduced toxicity conditioning with BU, fludarabine and alemtuzumab before the allogeneic hematopoietic SCT in children and adolescents. Bone Marrow Transplant 2011, 46:790-799.
5. Bhatia M., Militano O., Jin Z., et al. An age-dependent pharmacokinetic study of intravenous and oral mycophenolate mofetil in combination with tacrolimus for GVHD prophylaxis in pediatric allogeneic stem cell transplantation recipients. Biol Blood Marrow Transplant 2010, 16:333-343.
6. Satwani P., Baldinger L., Freedman J., et al. Incidence of Viral and fungal infections following busulfan-based reduced-intensity versus myeloablative conditioning in pediatric allogeneic stem cell transplantation recipients. Biol Blood Marrow Transplant 2009, 15:1587-1595.
7. Bradley M.B., Cairo M.S. Cord blood immunology and stem cell transplantation. Hum Immunol 2005, 66:431-446.
8. Cairo M.S., Rocha V., Gluckman E., et al. Alternative allogeneic donor sources for transplantation for childhood diseases: unrelated cord blood and haploidentical family donors. Biol Blood Marrow Transplant 2008, 14:44-53.
9. Freed J., Talano J., Small T., et al. Allogeneic cellular and autologous stem cell therapy for sickle cell disease: 'whom, when and how'. Bone Marrow Transplant 2012, 47:1489-1498.
10. Geyer M.B., Ricci A.M., Jacobson J.S., et al. T cell depletion utilizing CD34(+) stem cell selection and CD3(+) addback from unrelated adult donors in paediatric allogeneic stem cell transplantation recipients. Br J Haematol 2012, 157:205-219.